A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

Hoffmann-La Roche